Hydralazine's Effects on Tumor Blood Flow and Chemotherapy
Author Information
Author(s): P.K.M. Quinn, M.C. Bibby, J.A. Cox, S.M. Crawford
Primary Institution: University of Bradford
Hypothesis
Does hydralazine influence the vasculature and chemosensitivity of MAC tumors?
Conclusion
Hydralazine decreases tumor blood flow and enhances the efficacy of melphalan while increasing its toxicity.
Supporting Evidence
- Hydralazine caused an 80% vascular shutdown of well differentiated MAC 26 tumors.
- Hydralazine decreased MAC 26 perfusion by 63% and MAC 15A by 20%.
- Hydralazine enhanced the efficacy of melphalan by a factor of 2.1.
Takeaway
Hydralazine can help cancer drugs work better by changing how blood flows in tumors, but it can also make some treatments more harmful.
Methodology
The study used fluorescent dye and blood flow markers to assess tumor vasculature and perfusion, along with clonogenic assays to evaluate drug efficacy.
Limitations
The study's findings may not be applicable to tumors grown in different locations than subcutaneously.
Participant Demographics
Pure strain NMRI male mice, aged 6-8 weeks.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website